Key Points
- David Malcom Rodman sold 14,055 shares on Feb. 13 at an average of $27.44 for $385,669, leaving him with 44,089 shares (a 24.17% drop in his holdings, valued at about $1.21M).
- Rodman has been repeatedly liquidating large positions this year, including sales of 192,715 shares on Jan. 5 (~$6.75M) and 70,037 shares on Jan. 2 (~$2.51M), signaling substantial insider selling activity.
- MLYS trades near $27.60 with a market cap of roughly $2.18B and a 12‑month range of $8.24–$47.65; about 84.46% of the stock is institutionally owned and analysts have a consensus "Moderate Buy" price target of $47.43.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 6,349 shares of the business's stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $28.99, for a total value of $184,057.51. Following the completion of the transaction, the insider directly owned 50,437 shares of the company's stock, valued at approximately $1,462,168.63. This trade represents a 11.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
David Malcom Rodman also recently made the following trade(s):
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total value of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total transaction of $65,585.91.
- On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60.
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total value of $370,677.87.
- On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total value of $252,469.75.
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total value of $205,167.36.
- On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total value of $72,195.90.
- On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total value of $2,512,227.19.
- On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30.
Mineralys Therapeutics Stock Down 0.9%
MLYS stock opened at $27.60 on Friday. The stock has a market capitalization of $2.18 billion, a P/E ratio of -9.36 and a beta of 0.51. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $47.65. The firm has a 50-day simple moving average of $33.89 and a 200-day simple moving average of $33.41.
Analyst Ratings Changes
Several analysts recently commented on MLYS shares. Stifel Nicolaus boosted their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday, December 19th. Wells Fargo & Company upped their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Tuesday, November 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright boosted their price target on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a research report on Wednesday, November 12th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $47.43.
View Our Latest Stock Analysis on MLYS
Institutional Investors Weigh In On Mineralys Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Navalign LLC acquired a new position in Mineralys Therapeutics in the 4th quarter valued at about $33,000. Smartleaf Asset Management LLC increased its holdings in shares of Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock worth $40,000 after buying an additional 676 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company's stock valued at $54,000 after buying an additional 1,197 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Mineralys Therapeutics by 1,845.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock valued at $76,000 after acquiring an additional 1,993 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Mineralys Therapeutics in the second quarter worth approximately $91,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
